我们是否忽视了血液系统恶性肿瘤中的性别差异?呼吁改进报告
本文分析182项构成NCCN治疗指南基础的临床试验参考文献,发现17项(9.3%)未报告试验参与者性别分布,165项(90.6%)未报告按性别分层的结局;在报告了分层结局的试验中,36.5%显示结局存在性别差异。女性在试验学术领导和指南委员会中的比例显著低于其在专业中的代表性。作者呼吁在分析中纳入按性别分层的报告。
要点
- 182项构成NCCN指南基础的临床试验中,17项(9.3%)未报告性别分布,165项(90.6%)未报告按性别分层的结局。
- 在报告了性别分层结局的试验中,36.5%显示结局存在性别差异。
- 女性在试验学术领导及指南委员会中的比例显著低于其在专业中的代表性。
核心结论
- 作者呼吁临床试验领导者、联盟和指南制定者将按性别分层的数据纳入分析,并以透明方式报告,同时评估病因学因素是否因性别而异。
研究设计与样本
- 对构成近期美国国家综合癌症网络(NCCN)治疗指南基础的182项临床试验的参考文献进行分析。
主要发现
- 182项试验中,17项(9.3%)未报告试验参与者性别分布,165项(90.6%)未报告按性别分层的结局。
- 在报告了性别分层结局的试验中,36.5%显示结局存在性别差异。
- 女性在评估试验的学术领导层及指南委员会中的比例显著低于其在专业中的代表性。
临床怎么用
- 作者呼吁所有临床试验领导者、联盟和指南制定者在分析中纳入按性别分层的报告并透明呈现,研究者应评估病因学因素是否因性别而异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are clear sex-based differences in the incidence, risk factors and mortality of most haematologic malignancies (HM). Despite known differences in physiology, haematopoiesis, molecular profiles, drug pharmacokinetics, treatment-related toxicities and treatment experience, males and females receive standardized and identical treatment for most HMs. Previous published work has demonstrated disparities in female representation in cancer clinical trials and highlighted a paucity of information on differential treatment outcomes and toxicities by sex. We analysed references of 182 clinical trials which form the basis of recent treatment guidelines from the National Comprehensive Cancer Network and found a minority (17/9.3%) did not report the sex distribution of trial participants. However, a majority (165/90.6%) did not report sex-disaggregated outcomes. Of those that did, 36.5% showed outcome differences by sex. Academic leadership by women in the assessed trials as well as in guidelines committees was disproportionately lower than their representation in the profession. We call on all clinical trials leaders, consortia and guideline builders to include sex-disaggregated data in their analyses, reporting these in a transparent manner (as per regulations mandating such reporting), and for investigators to assess whether aetiological factors differ by sex. These actions will enhance personalized prevention, therapy and follow-up.
引用
- Paltiel O, Ratnasingam S, Lee HP, et al. Are we ignoring sex differences in haematological malignancies? A call for improved reporting. Br J Haematol. 2025. PMID: 40123129. doi:10.1111/bjh.20044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。